Open access
Open access
Powered by Google Translator Translator

Emergency Medicine

Study: Lateral flow antigen testing can rapidly and accurately detect early COVID-19 among patients presenting with flu-like illness and can be a plausible alternative to RT-PCR.

26 Jul, 2021 | 02:56h | UTC

Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2) – EClinicalMedicine

News release: Lateral flow tests are 95% effective at detecting Covid-19 when used at the onset of symptoms – University of Oxford

Related:

Interactive Infographic | Interpreting a lateral flow SARS-CoV-2 antigen test – “This calculator demonstrates how interpreting a covid-19 lateral flow device (LFD) result varies according to the pre-test probability, and the sensitivity and specificity of the LFD used”.

Rapid point-of-care tests for diagnosing COVID-19 infection: the latest Cochrane evidence

 

Commentary on Twitter (thread – click for more)

 

Case report: Kawasaki-like multisystem inflammatory syndrome associated with SARS-CoV-2 infection in an adult.

26 Jul, 2021 | 02:52h | UTC

Kawasaki-like multisystem inflammatory syndrome associated with SARS-CoV-2 infection in an adult – BMJ Case Reports

Related:

Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.

Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection

Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection

Case Reports: 2 Adults with Kawasaki-like Multisystem Inflammatory Syndrome Associated with COVID-19

 

Editorial | Antibiotic overuse: managing uncertainty and mitigating against overtreatment.

26 Jul, 2021 | 02:16h | UTC

Antibiotic overuse: managing uncertainty and mitigating against overtreatment – BMJ Quality & Safety

 

Commentary on Twitter

 

Review: Timing and completeness of revascularization in acute coronary syndromes.

26 Jul, 2021 | 02:21h | UTC

Timing and completeness of revascularisation in acute coronary syndromes – Heart

 

Commentary on Twitter

 

Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

23 Jul, 2021 | 10:51h | UTC

Tocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet

Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

 

Review: Ethics in extracorporeal life support.

23 Jul, 2021 | 10:29h | UTC

Ethics in extracorporeal life support: a narrative review – Critical Care

 

RCT: Immediate oral refeeding in patients with mild and moderate acute pancreatitis.

22 Jul, 2021 | 10:32h | UTC

Immediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial) – Annals of Surgery (link to abstract – $ for full-text)

 

A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia.

22 Jul, 2021 | 10:37h | UTC

A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia – Open Forum Infectious Diseases

 

Commentary on Twitter

 

Expert review | Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy.

21 Jul, 2021 | 10:37h | UTC

Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy – American Journal of Obstetrics & Gynecology

 

Commentary on Twitter

 

Cohort study: Sickle cell disorders and severe COVID-19 outcomes – “Our analysis estimated a 4-fold increased risk for COVID-19–related hospitalization and a 2.6-fold increased risk for COVID-19–related death for sickle cell disease”.

21 Jul, 2021 | 10:44h | UTC

Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine

 

WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).

20 Jul, 2021 | 10:29h | UTC

Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) – World Health Organization

Related Guidance: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.” AND ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

 

International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.

20 Jul, 2021 | 10:21h | UTC

Ischemic and Hemorrhagic Stroke Among Critically Ill Patients With Coronavirus Disease 2019: An International Multicenter Coronavirus Disease 2019 Critical Care Consortium Study – Critical Care Medicine

Related: SARS-CoV-2 and Stroke Characteristics – higher rate of large vessel occlusions and stroke in young patients AND Case series of 18 male adults aged 50 years or younger with acute ischemic stroke during the convalescent phase of asymptomatic Covid-19 AND Case-control study: COVID-19-associated stroke is associated with worse outcomes and increased mortality AND Pictorial essay: Neurological emergencies associated with COVID-19: stroke and beyond AND Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke AND Risk of Ischemic Stroke in Patients with COVID-19 vs. Patients with Influenza

 

WHO warns that HIV infection increases risk of severe and critical COVID-19.

20 Jul, 2021 | 10:24h | UTC

News release: WHO warns that HIV infection increases risk of severe and critical COVID-19 – World Health Organization

Report: WHO report on clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with SARS-CoV-2 infection

Related: M-A: Epidemiology and outcomes of COVID-19 in HIV-infected individuals – HIV is a significant risk factor for acquiring SARS-CoV-2 infection and is associated with a higher risk of mortality.

 

Commentary on Twitter (thread – click for more)

 

RCT: more data showing Azithromycin is not better than placebo in patients with Covid-19.

18 Jul, 2021 | 23:54h | UTC

Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial – JAMA

Commentary: Common antibiotic no more effective than placebo in preventing COVID-19 symptoms among non-hospitalized – University of California – San Francisco

Related: RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19. (several articles on the subject)

 

Commentary on Twitter

 

Position Paper: Recommendations for the use of topical inhalant budesonide in COVID-19.

18 Jul, 2021 | 23:53h | UTC

Recommendations for use of topical inhalant budesonide in COVID-19 – HNO

Related: RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19 AND Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

 

Review: Acute kidney injury.

18 Jul, 2021 | 23:18h | UTC

Acute kidney injury – Nature Reviews Disease Primers (free for a limited period)

 

Commentary on Twitter

 

Why was a major study on ivermectin for covid-19 just retracted?

16 Jul, 2021 | 11:11h | UTC

Why Was a Major Study on Ivermectin for COVID-19 Just Retracted? – Grifter Analysis and Review

See also: Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns – The Guardian AND Some problems in the dataset of a large study of Ivermectin for the treatment of Covid-19 – Nick Brown’s Blog AND Is Ivermectin for Covid-19 Based on Fraudulent Research? – Gideon M-K; Health Nerd

 

Commentary on Twitter (thread – click for more)

 

Short review: The gut in COVID-19.

16 Jul, 2021 | 10:54h | UTC

The gut in COVID-19 – Intensive Care Medicine

 

Commentary on Twitter

 

AAFP Guideline: Pharmacologic Management of COPD Exacerbations.

16 Jul, 2021 | 10:51h | UTC

Pharmacologic Management of COPD Exacerbations: A Clinical Practice Guideline from the AAFP – American Family Physician

 

RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease).

15 Jul, 2021 | 09:26h | UTC

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 – New England Journal of Medicine

 

Tramadol: Where do we go from here? – “Tramadol’s unpredictability, unique potential harms, and lack of advantage over other opioids or NSAIDs are now well recognized”.

15 Jul, 2021 | 09:14h | UTC

[131] Tramadol: Where do we go from here? – Therapeutic Initiative

 

M-A: Utility of intravenous Alteplase prior to endovascular stroke treatment.

15 Jul, 2021 | 09:03h | UTC

Utility of Intravenous Alteplase Prior to Endovascular Stroke Treatment: A Systematic Review and Meta-analysis of RCTs – Neurology (link to abstract – $ for full-text)

Commentary: Direct thrombectomy, bridging therapy confer similar functional outcomes in stroke – Healio (free registration required)

 

Commentary on Twitter

 

RCT: Lopinavir-ritonavir and hydroxychloroquine worsened outcomes in critically ill patients with COVID-19.

14 Jul, 2021 | 11:25h | UTC

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial – Intensive Care Medicine

 

Commentary on Twitter (thread – click for more)

 

RCT: Neither Remdesivir nor Hydroxychloroquine affect viral clearance in hospitalized patients with COVID-19.

14 Jul, 2021 | 11:23h | UTC

News release: Neither remdesivir nor HCQ affect viral clearance in hospitalized patients with COVID-19 – American College of Physicians

Original Study: Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 – Annals of Internal Medicine

 

Commentary on Twitter

 

FDA Safety Alert: hydroxyethyl starch products should not be used unless adequate alternative treatment is unavailable.

14 Jul, 2021 | 10:48h | UTC

Labeling Changes on mortality, kidney injury, and excess bleeding with hydroxyethyl starch products – U.S. Food and Drug Administration

Commentary: FDA Piles on New Warnings for Blood Volume Expanders – MedPage Today (free registration required)

Related: Hydroxyethyl-starch Solutions (HES) Should no Longer be Used – European Medicines Agency AND Randomized Trial: Hydroxyethyl Starch vs. Saline for Volume Replacement Therapy in High-Risk Patients Undergoing Major Abdominal Surgery AND Systematic Review: Colloids vs Crystalloids for Fluid Resuscitation in Critically Ill People

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.